According to the analytical report of DSM Group for 2016, the volume of the Russian pharmaceutical market reached 1344 billion rubles in 2016, which is 7% higher than a year earlier.
In 2016, the physical volumes of drug sales remained at the level of 2015 and amounted to 5.1 billion packages. The stabilization of consumption in terms of packages can be viewed as a turning trend because, in the past three years, this indicator of the pharmaceutical market was only declining.
The main contribution to the market growth was made by commercial segment of drugs. The trends of the retail market were positive in terms of packages, and the growth in ruble terms was generated mostly by OTC drugs. An important trend of contemporary market is its transition to generics, as their share is growing while the share of original drugs is declining both in monetary and physical terms.
Another trend of 2016 are the higher sales of Russian-made medicines. In 2016, the overall share of Russian-made drugs in the market was 29% in monetary terms and 61% in terms of sold packages. The share of imported medicines is shrinking, while the Russian-made drugs take an increasingly larger part of the market. The processes of import substitution are most noticeable in the public segment. This was facilitated by the Decree on the restriction of public procurement of imported medicines (“odd man out” rule). But nevertheless, the balance shift between Russian-made and imported drugs is going too slowly. As a result, the top positions in the ranking of manufacturers are held by foreign companies, such as Sanofi, Novartis, and Bayer.